Audiological Monitoring for Ototoxicity in Medically Fragile Children

ABSTRACT

Risk for hearing loss due to medical interventions has audiological as well as medicolegal implications. In children with life-threatening conditions, medical interventions may require great risk of morbidity to reduce mortality. Although audiologists are typically not in the position of intervening to rescue hearing, they do provide necessary and timely information when ototoxicity monitoring protocols are in place and followed. As well, knowing specific risk indicators can help the audiologist participate in efforts to minimize likelihood for and severity of hearing loss. Identifying risk indicators specific to a patient's history can help the audiologist counsel the family regarding the individual patient's risk for developing hearing loss and what audiological interventions may be appropriate should hearing loss occur. It is the role of the audiologist to provide thoughtful surveillance for hearing loss and interventions to minimize the impact of hearing loss when it occurs.

KEYWORDS

ECMO - cystic fibrosis - tumors - aminoglycosides - chemotherapy

REFERENCES

• 1 Wang J, Puel J L, Bobbin R. Mechanisms of toxicity in the cochlea. In: Campbell K CM, ed. Pharmacology and Ototoxicity for Audiologists. Clifton Park, NY: Thomson Delmar Learning; 2007: 70-85
• 2 Fedtke T, Richter U. Reference zero for the calibration of air-conduction audiometric equipment using “tone bursts” as test signals.  Int J Audiol. 2007;  46 1-10
• 3 Fausti S A, Helt W J, Gordon J S, Reavis K M, Phillips D S, Konrad-Martin D L. Audiologic monitoring for ototoxicity and patient management. In: Campbell K CM, ed. Pharmacology and Ototoxicity for Audiologists. Clifton Park, NY: Thomson Delmar Learning; 2007: 230-251
• 4 National Cancer Institute Common Toxicity Criteria for Adverse Events v. 4.0. 2009. Cancer therapy evaluation program. U.S. DHHS, NIH, NCI
• 5 Extracorporeal Life Support Organization .ECMO Registry of the Extracorporeal Life Support Organization (ELSO). Ann Arbor, MI: Extracorporeal Life Support Organization; 2002
• 6 Graziani L J, Gringlas M, Baumgart S. Cerebrovascular complications and neurodevelopmental sequelae of neonatal ECMO.  Clin Perinatol. 1997;  24 655-675
• 7 Fligor B J, Neault M W, Mullen C H, Feldman H A, Jones D T. Factors associated with sensorineural hearing loss among survivors of extracorporeal membrane oxygenation therapy.  Pediatrics. 2005;  115 1519-1528
• 8 American Academy of Pediatrics Joint Committee on Infant Hearing . Joint Committee on Infant Hearing 2007 Position Statement.  Pediatrics. 2007;  95 898-921
• 9 Cheung P Y, Robertson C M. Sensorineural hearing loss in survivors of neonatal extracorporeal membrane oxygenation.  Pediatr Rehabil. 1997;  1 127-130
• 10 American Academy of Pediatrics Joint Committee on Infant Hearing . Joint Committee on Infant Hearing 1994 Position Statement.  Pediatrics. 1995;  95 152-156
• 11 Cheng A G, Johnston P R, Luz J et al.. Sensorineural hearing loss in patients with cystic fibrosis.  Otolaryngol Head Neck Surg. 2009;  141 86-90
• 12 Rybak L P, Huang X, Campbell K CM. Cancer and ototoxicity of chemotherapeutics. In: Campbell K CM, ed. Pharmacology and Ototoxicity for Audiologists. Clifton Park, NY: Thomson Delmar Learning; 2007: 138-162
• 13 Brock P R, Bellman S C, Yeomans E C, Pinkerton C R, Pritchard J. Cisplatin ototoxicity in children: a practical grading system.  Med Pediatr Oncol. 1991;  19 295-300
• 14 Lewis M J, DuBois S G, Fligor B J, Li X, Goorin A, Grier H E. Ototoxicity in children treated for osteosarcoma.  Pediatr Blood Cancer. 2009;  52 387-391
• 15 Li Y, Womer R B, Silber J H. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.  Eur J Cancer. 2004;  40 2445-2451
• 16 Schell M J, McHaney V A, Green A A et al.. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation.  J Clin Oncol. 1989;  7 754-760
• 17 Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma.  Oncologist. 2004;  9 422-441
• 18 Link M P, Goorin A M, Horowitz M et al.. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study.  Clin Orthop Relat Res. 1991;  270 8-14
• 19 Ratain M. Pharmacokinetics and pharmacodynamics. In: DeVita V T, Hellman S, Rosenberg S A, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 335-344
• 20 Stelmachowicz P G, Pittman A L, Hoover B M, Lewis D E, Moeller M P. The importance of high-frequency audibility in the speech and language development of children with hearing loss.  Arch Otolaryngol Head Neck Surg. 2004;  130 556-562